You can buy or sell Celldex and other stocks, options, ETFs, and crypto commission-free!
Celldex Therapeutics, Inc. engages in the research, development, and commercialization of immunotherapies and other targeted biologics. Its drug candidates have the ability to engage the human immune system and directly inhibit tumors to treat specific types of cancer and other diseases. Read More Its pipeline includes Varlilumab, CDX-1140, and CDX-301, and CDX-3379. The company was founded by Anthony S. Marucci and Tibor Keler in 1983 and is headquartered in Hampton, NJ.
Hampton, New Jersey
52 Week High
52 Week Low
Yahoo FinanceMay 7
Celldex Therapeutics (CLDX) Reports Q1 Loss, Tops Revenue Estimates
Celldex (CLDX) delivered earnings and revenue surprises of 0.88% and 13.10%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Yahoo FinanceMay 7
Celldex Provides Corporate Update and Reports First Quarter 2019 Results
HAMPTON, N.J., May 07, 2019 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (CLDX) today reported business and financial highlights for the first quarter ended March 31, 2019. “Celldex presented positive data across multiple programs at AACR in April, including from our promising CDX-1140 program,” said Anthony Marucci, Co-founder, President and Chief Executive Officer of Celldex Therapeutics. “We have successfully cleared a critical hurdle for CD40 agonists, reaching dose levels with good systemic exposure...
Celldex Therapeutics (CLDX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
Celldex Therapeutics (CLDX) is expected to deliver a year-over-year increase in earnings on lower revenues when i t report s results for the quarter ended March 2019. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.
Expected Aug 8, After Hours